Supernus Pharmaceuticals price target raised to $43 from $38 at Stifel

Published 06/08/2025, 16:16
Supernus Pharmaceuticals price target raised to $43 from $38 at Stifel

Investing.com - Stifel raised its price target on Supernus Pharmaceuticals (NASDAQ:SUPN) to $43.00 from $38.00 on Wednesday, while maintaining a Hold rating on the stock. According to InvestingPro data, the stock is currently trading near its 52-week high, with a market capitalization of $2.66 billion.

The price target increase follows Supernus’s strong second-quarter 2025 performance, with revenues of $165.5 million exceeding consensus estimates of $154.1 million. The company’s growth was primarily driven by increasing traction with its Qelbree and Gocovri products, supported by impressive gross profit margins of 88.53%.

Supernus has recently diversified its portfolio with the approval of Onapgo pump for severe Parkinson’s disease, completing its movement disorder offerings. The company also closed its acquisition of SAGE for Zurzuvae, a treatment for post-partum depression. InvestingPro analysis reveals 12+ additional insights about SUPN’s growth potential and financial health.

Following the SAGE acquisition, Supernus updated its fiscal year 2025 guidance, raising revenue expectations to $670-700 million from the previous $600-630 million range. The company maintained its non-GAAP operating income guidance at $105-135 million.

Supernus reported cash holdings of $522.6 million, with approximately $240-260 million on a pro forma basis, which Stifel believes positions the company well for continued investment in both products and pipeline development.

In other recent news, Supernus Pharmaceuticals reported its second-quarter 2025 earnings, showing a mixed financial performance. The company’s revenue reached $165 million, exceeding the forecast of $154.3 million by 7.26%. However, earnings per share (EPS) were $0.40, falling short of the anticipated $0.48 by 16.67%. These results highlight a divergence between revenue growth and profit expectations. Despite the earnings miss, the revenue beat is notable for investors keeping an eye on the company’s financial health. Analyst firms have not provided any recent upgrades or downgrades, leaving the focus on Supernus’s earnings performance. Investors may find these developments significant when considering the company’s future potential.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.